Phenylbutyrate counteracts Shigella mediated downregulation of cathelicidin in rabbit lung and intestinal epithelia: a potential therapeutic strategy.

Abstract

BACKGROUND:

Cathelicidins and defensins are endogenous antimicrobial peptides (AMPs) that are downregulated in the mucosal epithelia of the large intestine in shigellosis. Oral treatment of Shigella infected rabbits with sodium butyrate (NaB) reduces clinical severity and counteracts the downregulation of cathelicidin (CAP-18) in the large intestinal epithelia.

AIMS:

To develop novel regimen for treating infectious diseases by inducing innate immunity, we selected sodium 4-phenylbutyrate (PB), a registered drug for a metabolic disorder as a potential therapeutic candidate in a rabbit model of shigellosis. Since acute respiratory infections often cause secondary complications during shigellosis, the systemic effect of PB and NaB on CAP-18 expression in respiratory epithelia was also evaluated.

METHODS:

The readouts were clinical outcomes, CAP-18 expression in mucosa of colon, rectum, lung and trachea (immunohistochemistry and real-time PCR) and release of the CAP-18 peptide/protein in stool (Western blot).

PRINCIPAL FINDINGS:

Significant downregulation of CAP-18 expression in the epithelia of rectum and colon, the site of Shigella infection was confirmed. Interestingly, reduced expression of CAP-18 was also noticed in the epithelia of lung and trachea, indicating a systemic effect of the infection. This suggests a causative link to acute respiratory infections during shigellosis. Oral treatment with PB resulted in reduced clinical illness and upregulation of CAP-18 in the epithelium of rectum. Both PB and NaB counteracted the downregulation of CAP-18 in lung epithelium. The drug effect is suggested to be systemic as intravenous administration of NaB could also upregulate CAP-18 in the epithelia of lung, rectum and colon.

CONCLUSION:

Our results suggest that PB has treatment potential in human shigellosis. Enhancement of CAP-18 in the mucosal epithelia of the respiratory tract by PB or NaB is a novel discovery. This could mediate protection from secondary respiratory infections that frequently are the lethal causes in dysentery.

• Authors: Protim Sarker, Sultan Ahmed, Snigdha Tiash, Rokeya Sultana Rekha, Roger Stromberg, Jan Andersson, Peter Bergman, Gudmundur H Gudmundsson, Birgitta Agerberth, Rubhana Raqib
• Journal: PloS one (PLoS One) Vol. 6 Issue 6 Pg. e20637 ( 2011) ISSN: 1932-6203 [Electronic] United States
• PMID: 21673991 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Antimicrobial Cationic Peptides
• Phenylbutyrates
• RNA, Messenger
• Cathelicidins

Topics

• Administration, Oral
• Amino Acid Sequence
• Animals
• Antimicrobial Cationic Peptides (chemistry, genetics, metabolism)
• Bacterial Load (drug effects)
• Down-Regulation (drug effects)
• Dysentery, Bacillary (drug therapy)
• Feces (microbiology)
• Intestinal Mucosa (drug effects, metabolism, microbiology)
• Intestine, Large (drug effects, metabolism, microbiology)
• Lung (drug effects, metabolism, microbiology)
• Molecular Sequence Data
• Phenylbutyrates (adverse effects, pharmacology, therapeutic use)
• RNA, Messenger (genetics, metabolism)
• Rabbits
• Shigella (drug effects, pathogenicity)
• Trachea (drug effects, metabolism, microbiology)
• Cathelicidins